CustomCustomCustomCustomCustomCustom
1 10, 2020

Dr. Michael Nodine´s Spike-in technology is nominated for a Houska prize

2023-03-10T10:28:48+01:00October 1st, 2020|biomarker, microRNA, microRNA services, Personalized medicine, safety, test service|Comments Off on Dr. Michael Nodine´s Spike-in technology is nominated for a Houska prize

The “Houska“ Prize, awarded annually by the B&C Foundation, is Austria´s biggest private award for applied research. Dr. Michael Nodine, Gregor Mendel Institute of Molecular Plant Biology (GMI), was nominated for his work on the development of methods for nucleic acid quantification. A major issue they encountered was the lack of absolute quantification of small RNA levels, making the comparison between tissues difficult. To overcome this problem, Michael and his team, developed a set of synthetic small RNA Spike-Ins that could be added to these tissue samples. This technology allows us to accurately quantify the levels of different small RNAs that could play a role in several human diseases, ranging from cancer to cardiovascular disease. In 2019, GMI [...]

Read More
5 11, 2019

Combining laser microdissection and microRNA expression profiling to unmask microRNA signatures in complex tissues

2023-03-10T10:56:26+01:00November 5th, 2019|biomarker, biomarkers, drug development, drug discovery, LMD, microRNAs, Personalized medicine, safety, Vivomicx|Comments Off on Combining laser microdissection and microRNA expression profiling to unmask microRNA signatures in complex tissues

We want to draw your attention to the latest publication with our partner Vivomicx. Together we have developed a combination of laser microdissection (LMD) and high quality qPCR, which enables the quantitative analysis of cell-type specific RNA expression in complex tissues. Using this protocol TAmiRNA & Vivomicx have been able to demonstrate: the profound difference of RNA expression between whole tumor and subsets of cells within the tumor and the large heterogeneity in RNA expression between colorectal* tumor compartments such as tumor, stroma and tumor endothelial cells. * Note: the technology can be utilized for almost any tissue sample. Our new approch allows to: Discover differential expression patterns between “healthy” and “diseased” tissues on the cellular level; [...]

Read More
26 06, 2019

University Medical Center Groningen (UMCG) , TAmiRNA GmbH & Vivomicx BV announce their collaboration to unmask the molecular signature of sepsis induced multi organ failure.

2023-03-10T10:59:37+01:00June 26th, 2019|biomarkers, LMD, microRNAs, safety, Vivomicx|Comments Off on University Medical Center Groningen (UMCG) , TAmiRNA GmbH & Vivomicx BV announce their collaboration to unmask the molecular signature of sepsis induced multi organ failure.

UMCG, TAmiRNA, and Vivomicx today announced their collaboration to unmask the molecular signature of sepsis induced multi organ failure and shed light on diagnosis and therapeutic options. Sepsis is the body’s response to infection. Sepsis kills and disables millions of patients worldwide. The role of the microvasculature in all organs has been identified as central, yet understudied in the pathophysiology leading to Multi Organ Failure (MOF) in critically ill patients with sepsis. This translational project combines cutting edge molecular research at the level of kinome, gene expression, and microRNome in samples of patients who suffered from sepsis and of animal models of this disease. In both human and mouse lungs and kidneys we will enrich the samples [...]

Read More
30 04, 2019

TAmiRNA is part of the international IMI2 project “Translational Safety Biomarker Pipeline”

2023-03-10T11:01:16+01:00April 30th, 2019|biomarkers, drug development, drug discovery, exosomes, liquid biopsies, microRNAs, Personalized medicine, safety|Comments Off on TAmiRNA is part of the international IMI2 project “Translational Safety Biomarker Pipeline”

Early and reliable detection and monitoring of adverse events is essential for improving of patient safety, reducing late attrition of drug candidates, and enhancing understanding of toxic mechanisms. The Translational Safety Biomarker Pipeline (TransBioLine) project will focus on development of biomarkers of injury for liver, kidney, pancreas, vasculature, central nervous system (CNS) and the development of non-invasive microRNA biomarkers using liquid biopsies. The project is coordinated by the University of Zurich with Pfizer as industry lead, and involves 27 partners (pharmaceutical companies, small and medium-sized enterprises, and academic institutions) from ten European countries and the United States of America. With a total budget of € 28 million, the EU and the pharmaceutical companies involved are financing the [...]

Read More
30 04, 2019

TAmiRNA and advanceCOR receive Eurostars project “thrombomiR”

2023-03-10T11:01:46+01:00April 30th, 2019|biomarkers, drug development, drug discovery, microRNAs, Personalized medicine, safety, thrombomiR|Comments Off on TAmiRNA and advanceCOR receive Eurostars project “thrombomiR”

TAmiRNA and advanceCOR, a drug developing biotechnology company which focuses on personalized medicine in cardiovascular diseases, receive Eurostars project entitled: ”A novel microRNA-based platelet function biomarker for personalized anti-thrombotic treatment”.  The aim of the Eurostars project is to validate the use of the thrombomiR™ kit for management of anti-thrombotic therapies. The thrombomiR™ kit is a minimally invasive blood test that can determine changes in platelets reactivity (for example due to a therapy), based on the quantitative analysis of microRNAs, Specifically, the thrombomiR™ kit allows the targeted detection and quantitation of platelet-specific microRNAs in blood plasma. The concentration of these microRNAs increases in the course of activation of platelets and decreases as a result of therapeutic inactivation. Thus, [...]

Read More
© Copyright TAmiRNA 2019 - 
 
Go to Top